Indian Pharma companies are now moving up the value chain with the ultimate goal to become global R&D hubs in-line with the Governmnet’s vision to make India a Global Knowledge Center. Leading Pharmaceutical Companies in CRAMs (Contract Research and Manufacturing Services) segment – Biocon, Dishman Pharmaceuticals, Jubilant Organosys and Piramal Healthcare.
In the current scenario, the outlook for CRAMs companies remain robust as the R&D productivity of global pharmaceutical companies is constantly declining and ever increasing costs for discovering new molecules, will force these companies to reduce costs and improve productivity. Consequently they are forced to shift some of their manufacturing activity to the low cost labour intensive countries like India which offer both quality and cost advantage.
Various Research including that of KPMG indicate that the global opportunity in Contract Manufacturing and Research are pegged at ~USD 21 bn and at ~USD 14 bn, respectively.